BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37030072)

  • 21. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary Ovarian Cancer and Risk Reduction.
    Andrews L; Mutch DG
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():31-48. PubMed ID: 28254144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
    Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience.
    Nagashima M; Ishikawa T; Asami Y; Hirose Y; Shimada K; Miyagami S; Mimura T; Miyamoto S; Onuki M; Morioka M; Izumi M; Yoshida R; Yamochi T; Taruno K; Nakamura S; Sekizawa A; Matsumoto K
    Jpn J Clin Oncol; 2023 Jun; 53(6):472-479. PubMed ID: 36999211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
    Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
    Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome.
    Wright JD; Silver ER; Tan SX; Hur C; Kastrinos F
    JAMA Netw Open; 2021 Sep; 4(9):e2123616. PubMed ID: 34499134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
    J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy.
    Manchanda R; Silvanto A; Abdelraheim A; Burnell M; Johnson M; Saridogan E; Rosenthal AN; Brunell C; Aslam N; Vashisht A; Pandis G; Jacobs I; Menon U; Benjamin E
    Int J Gynecol Cancer; 2012 Jun; 22(5):881-8. PubMed ID: 22572844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
    JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    Seppälä TT; Dominguez-Valentin M; Crosbie EJ; Engel C; Aretz S; Macrae F; Winship I; Capella G; Thomas H; Hovig E; Nielsen M; Sijmons RH; Bertario L; Bonanni B; Tibiletti MG; Cavestro GM; Mints M; Gluck N; Katz L; Heinimann K; Vaccaro CA; Green K; Lalloo F; Hill J; Schmiegel W; Vangala D; Perne C; Strauß HG; Tecklenburg J; Holinski-Feder E; Steinke-Lange V; Mecklin JP; Plazzer JP; Pineda M; Navarro M; Vida JB; Kariv R; Rosner G; Piñero TA; Pavicic W; Kalfayan P; Ten Broeke SW; Jenkins MA; Sunde L; Bernstein I; Burn J; Greenblatt M; de Vos Tot Nederveen Cappel WH; Della Valle A; Lopez-Koestner F; Alvarez K; Büttner R; Görgens H; Morak M; Holzapfel S; Hüneburg R; von Knebel Doeberitz M; Loeffler M; Redler S; Weitz J; Pylvänäinen K; Renkonen-Sinisalo L; Lepistö A; Hopper JL; Win AK; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Therkildsen C; Wadt KAW; Mourits MJE; Ketabi Z; Denton OG; Rødland EA; Vasen H; Neffa F; Esperon P; Tjandra D; Möslein G; Rokkones E; Sampson JR; Evans DG; Møller P
    Eur J Cancer; 2021 May; 148():124-133. PubMed ID: 33743481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.